Vest Financial LLC Has $72.41 Million Holdings in AbbVie Inc. $ABBV

Vest Financial LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.9% in the third quarter, Holdings Channel.com reports. The fund owned 312,742 shares of the company’s stock after selling 9,478 shares during the quarter. AbbVie makes up approximately 0.9% of Vest Financial LLC’s investment portfolio, making the stock its 13th biggest position. Vest Financial LLC’s holdings in AbbVie were worth $72,412,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Evolution Wealth Management Inc. acquired a new position in AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the second quarter worth approximately $36,000. Delos Wealth Advisors LLC bought a new stake in AbbVie in the second quarter worth approximately $39,000. Finally, Bear Mountain Capital Inc. lifted its stake in AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $213.90 on Wednesday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market cap of $378.04 billion, a price-to-earnings ratio of 162.05, a PEG ratio of 0.88 and a beta of 0.36. The business’s fifty day moving average is $226.50 and its 200 day moving average is $216.99.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter last year, the business posted $3.00 earnings per share. The firm’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is presently 524.24%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ABBV. Guggenheim raised their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Morgan Stanley upped their target price on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $248.11.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.